Literature DB >> 31853045

Different effects of the deletion of angiotensin converting enzyme 2 and chronic activation of the renin-angiotensin system on muscle weakness in middle-aged mice.

Hikari Takeshita1, Koichi Yamamoto2, Masaki Mogi3, Satoko Nozato1, Masatsugu Horiuchi4, Hiromi Rakugi1.   

Abstract

Inhibition of the renin-angiotensin system (RAS) has been shown to alleviate muscle atrophy both under pathological conditions and during physiological aging. We recently reported that the deletion of angiotensin converting enzyme 2 (ACE2), which converts Angiotensin II to Angiotensin-(1-7) in mice, leads to the early manifestation of aging-associated muscle weakness along with the increased expression of p16INK4a, a senescence-associated gene, and increased central nuclei in the tibialis anterior (TA) muscle in middle age. As ACE2 is multifunctional and functions beyond its role in the RAS, we investigated whether activation of the RAS primarily contributes to muscle weakness in ACE2 knockout (KO) mice by comparing these mice to Tsukuba hypertensive (TH) mice that overproduce human angiotensin II. The grip strength of young (6 months) and middle-aged (15 months) TH mice was consistently lower than that of wild-type mice at the same ages. Middle-aged TH mice were continuously lean with extremely reduced adiposity. Central nuclei in the gastrocnemius (GM) muscle were increased in ACE2KO mice, while no apparent morphological change was observed in the GM muscles of TH mice. Increased expression of p16INK4a along with alterations in the expression of several sarcopenia-associated genes were observed in the GM muscles of ACE2KO mice but not TH mice. These findings suggest that chronic overactivation of the RAS does not primarily contribute to the early aging phenotypes of skeletal muscle in ACE2KO mice.

Entities:  

Keywords:  ACE2; Renin-angiotensin system; Sarcopenia; Skeletal muscle; angiotensin II

Mesh:

Substances:

Year:  2019        PMID: 31853045     DOI: 10.1038/s41440-019-0375-7

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  38 in total

1.  Losartan restores skeletal muscle remodeling and protects against disuse atrophy in sarcopenia.

Authors:  Tyesha N Burks; Eva Andres-Mateos; Ruth Marx; Rebeca Mejias; Christel Van Erp; Jessica L Simmers; Jeremy D Walston; Christopher W Ward; Ronald D Cohn
Journal:  Sci Transl Med       Date:  2011-05-11       Impact factor: 17.956

2.  Muscle-specific expression of IGF-1 blocks angiotensin II-induced skeletal muscle wasting.

Authors:  Yao-Hua Song; Yangxin Li; Jie Du; William E Mitch; Nadia Rosenthal; Patrick Delafontaine
Journal:  J Clin Invest       Date:  2005-02       Impact factor: 14.808

3.  Angiotensin II Induces Skeletal Muscle Atrophy by Activating TFEB-Mediated MuRF1 Expression.

Authors:  Philipp Du Bois; Cristina Pablo Tortola; Doerte Lodka; Melanie Kny; Franziska Schmidt; Kunhua Song; Sibylle Schmidt; Rhonda Bassel-Duby; Eric N Olson; Jens Fielitz
Journal:  Circ Res       Date:  2015-07-02       Impact factor: 17.367

Review 4.  A review of sarcopenia: Enhancing awareness of an increasingly prevalent disease.

Authors:  Eric Marty; Yi Liu; Andre Samuel; Omer Or; Joseph Lane
Journal:  Bone       Date:  2017-09-18       Impact factor: 4.398

5.  Losartan, a therapeutic candidate in congenital muscular dystrophy: studies in the dy(2J) /dy(2J) mouse.

Authors:  Moran Elbaz; Nurit Yanay; Shlomit Aga-Mizrachi; Zivia Brunschwig; Ibaa Kassis; Keren Ettinger; Vivian Barak; Yoram Nevo
Journal:  Ann Neurol       Date:  2012-05       Impact factor: 10.422

6.  Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states.

Authors:  Ronald D Cohn; Christel van Erp; Jennifer P Habashi; Arshia A Soleimani; Erin C Klein; Matthew T Lisi; Matthew Gamradt; Colette M ap Rhys; Tammy M Holm; Bart L Loeys; Francesco Ramirez; Daniel P Judge; Christopher W Ward; Harry C Dietz
Journal:  Nat Med       Date:  2007-01-21       Impact factor: 53.440

Review 7.  Invited review: Aging and sarcopenia.

Authors:  Timothy J Doherty
Journal:  J Appl Physiol (1985)       Date:  2003-10

Review 8.  Renin-angiotensin system: an old player with novel functions in skeletal muscle.

Authors:  Claudio Cabello-Verrugio; María Gabriela Morales; Juan Carlos Rivera; Daniel Cabrera; Felipe Simon
Journal:  Med Res Rev       Date:  2015-03-11       Impact factor: 12.944

9.  Angiotensin II receptor type 1 blockade decreases CTGF/CCN2-mediated damage and fibrosis in normal and dystrophic skeletal muscles.

Authors:  Claudio Cabello-Verrugio; María Gabriela Morales; Daniel Cabrera; Carlos P Vio; Enrique Brandan
Journal:  J Cell Mol Med       Date:  2012-04       Impact factor: 5.310

10.  Angiotensin II receptor blockade promotes repair of skeletal muscle through down-regulation of aging-promoting C1q expression.

Authors:  Chizuru Yabumoto; Hiroshi Akazawa; Rie Yamamoto; Masamichi Yano; Yoko Kudo-Sakamoto; Tomokazu Sumida; Takehiro Kamo; Hiroki Yagi; Yu Shimizu; Akiko Saga-Kamo; Atsuhiko T Naito; Toru Oka; Jong-Kook Lee; Jun-Ichi Suzuki; Yasushi Sakata; Etsuko Uejima; Issei Komuro
Journal:  Sci Rep       Date:  2015-09-25       Impact factor: 4.379

View more
  5 in total

Review 1.  Tryptophan Metabolism and COVID-19-Induced Skeletal Muscle Damage: Is ACE2 a Key Regulator?

Authors:  Hikari Takeshita; Koichi Yamamoto
Journal:  Front Nutr       Date:  2022-04-08

Review 2.  ACE2, angiotensin 1-7 and skeletal muscle: review in the era of COVID-19.

Authors:  Koichi Yamamoto; Hikari Takeshita; Hiromi Rakugi
Journal:  Clin Sci (Lond)       Date:  2020-11-27       Impact factor: 6.124

Review 3.  Control of aging by the renin-angiotensin system: a review of C. elegans, Drosophila, and mammals.

Authors:  Brian M Egan; Andrea Scharf; Franziska Pohl; Kerry Kornfeld
Journal:  Front Pharmacol       Date:  2022-09-14       Impact factor: 5.988

4.  Endothelial Senescence and Chronic Fatigue Syndrome, a COVID-19 Based Hypothesis.

Authors:  Adonis Sfera; Carolina Osorio; Carlos M Zapata Martín Del Campo; Shaniah Pereida; Steve Maurer; Jose Campo Maldonado; Zisis Kozlakidis
Journal:  Front Cell Neurosci       Date:  2021-06-25       Impact factor: 5.505

Review 5.  Targeting Molecular Mechanism of Vascular Smooth Muscle Senescence Induced by Angiotensin II, A Potential Therapy via Senolytics and Senomorphics.

Authors:  Keisuke Okuno; Stephanie Cicalese; Katherine J Elliott; Tatsuo Kawai; Tomoki Hashimoto; Satoru Eguchi
Journal:  Int J Mol Sci       Date:  2020-09-09       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.